Advanced HER2-positive gastric cancer: Current and future targeted therapies

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 350-362

  Pazo Cid, Roberto A ^a   Antón, Antonio ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Gastric cancer; Human epidermal growth factor receptor; Multitargeted tyrosine kinase inhibitors; Second line therapies; Targeted therapies; Trastuzumab resistance

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; AFATINIB; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; EVEROLIMUS; FLUOROURACIL; FORETINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GSK 136089; HEAT SHOCK PROTEIN 90 INHIBITOR; HM 781 36B; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; RILOTUMUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TRASTUZUMAB PB 212; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CHROMOSOME 17 POLYSOMY; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; NONHUMAN; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84873522129     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.08.008     Document Type: Review

References (121)

1. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts and figures 2007 2007, American Cancer Society, Atlanta, GA.
2. Sant M., Allemani C., Santaquilani M., et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. European Journal of Cancer 2009, 45:931-991.
3. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2010, 3:CD004064.
4. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology 2006, 24:4991-4997.
5. Cunningham D., Starling N., Sheela Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine 2008, 358:36-46.
6. Okines A., Norman A., McCloud P., et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Annals of Oncology 2009, 20:1529-1534.
7. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology 2005, 16:273-278.
8. Matsui Y., Inomata M., Tojigamori M., et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a urine model. International Journal of Oncology 2005, 27:681-685.
9. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687-697.
10. Grávalos C., Gimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology 2008, 16:273-278.
11. Akiyama T., Sudo C., Ogawara H., et al. The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science 1986, 232:644-1646.
12. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer 2007, 97:453-457.
13. Okines A., Cunningham D., Chau I. Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 2011, 8:492-503.
14. Yonemura Y., Ninomiya I., Yamaguchi A., et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Research 1991, 51:1034-1038.
15. Uchino S., Tsuda H., Maruyama K., et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993, 72:3179-3184.
16. Mizutani T., Onda M., Tokunaga A., et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993, 72:2083-2088.
17. Shun C.T., Wu M.S., Lin J.T., et al. Relationship of p53 and c-erbB-2 expression to histopathological features. Helicobacter pylori infection and prognosis in gastric cancer. Hepato-Gastroenterology 1997, 44:604-609.
18. Nakajima M., Sawada H., Yamada Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
19. Allgayer H., Babic R., Gruetzner K.U., et al. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor associated protease systems. Journal of Clinical Oncology 2000, 18:2201-2209.
20. Garcia I., Vizoso F., Martin A., et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Annals of Surgical Oncology 2003, 10:234-241.
21. Park D.I., Yun J.W., Park J.H., et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Digestive Diseases and Sciences 2006, 51:1371-1379.
22. Tateishi M., Toda T., Minamisono Y., et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surgical Oncology 1992, 49:209-212.
23. Sasano H., Date F., Imatani A., et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Human Pathology 1993, 24:584-589.
24. Song H.S., Do Y.R., Kim I.H., Sohn S.S., Kwon K.Y. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Research and Treatment 2004, 36:240-245.
25. Matsubara J., Yamada Y., Hirashima Y., et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clinical Cancer Research 2008, 14:3022-3029.
26. Shah M.A., Janjigian Y.Y., Pauligk C., et al. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: a U.S. and European international collaborative analysis. Journal of Clinical Oncology 2011, 29s. [Abstract 4014].
27. Yoon H.H., Shi Q., Sukov W.T., et al. HER2 expression/amplification: frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology 2011, 29s. [Abstract 4012].
28. Phillips B.E., Tubbs R.R., Rice T.W., et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). Journal of Clinical Oncology 2011, 29s. [Abstract 4046].
29. Terashima M., Ochiai A., Kitada K., et al. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. Journal of Clinical Oncology 2011, 29s. [Abstract 4013].
30. Park Y.S., Ryu M., Park H.J., et al. HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. Journal of Clinical Oncology 2011, 29s. [Abstract 4084].
31. Grabsh H., Sivakumar S., Gray S., Gabbert H.E., Mulller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent case series. Cellular Oncology 2010, 32:57-65.
32. Linos K., Sheehan C.E., Ross J.S., et al. Correlation of HER2 and PTEN status with clinical outcome in esophageal, gastric, and gastroesophageal junction adenocarcinomas. Journal of Clinical Oncology 2011, 29s. [Abstract 4066].
33. Hsu J.-T., Chen T.-Ch, Tseng J.-H., et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1036 patients. Oncologist 2011, 16:1706-1713.
34. Van Cutsem E., de Haas S., Kang Y.-K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a bioarker evaluation from the AVAGAST randomized phase III trial. Journal of Clinical Oncology 2012, [Epub ahead of print]. 10.1200/JCO.2011.39.9824.
35. Jácome A.A., Wohnrath D.R., Neto C.S., et al. Prognostic value of epidermal growth factor receptors (EGFR) on overall survival of gastric cancer patients. Journal of Clinical Oncology 2012, 30s. [Abstract e14599].
36. Perez-Fidalgo J.A., Tarazona N., Navarro S., et al. Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer. Journal of Clinical Oncology 2012, 30s. [Abstract e14589].
37. Kim K.C., Koh Y.W., Chang H.M., et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Annals of Surgical Oncology 2011, [Epub ahead of print]. 10.1245/s10434-011-1695-2.
38. Begnami M.D., Fukuda E., Fregnani J., et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. Journal of Clinical Oncology 2011, 29:3030-3036.
39. Zhang X.L., Yang Y.S., Xu D.P., et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World Journal of Surgery 2009, 33:2112-2118.
40. Barros-Silva J.D., Leitão D., Afonso L., et al. Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients. British Journal of Cancer 2009, 100:488-493.
41. Zhou F., Li N., Hua Z., et al. Prognosis significance of HER2/neu overexpression and amplification in patients with curatively resected gastric cancer. Journal of Clinical Oncology 2012, 30s. [Abstract e14539].
42. Bria E., Barbi S., De Manzoni G., et al. Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: a clinical-biological risk stratification model. Journal of Clinical Oncology 2012, 30s. [Abstract 4076].
43. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
44. Rüschoff J., Dietel M., Baretton G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 2010, 457:299-307.
45. Yang J., Luo H., Li J., et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochemistry and Biophysics 2012, 62:221-228.
46. Bang Y., Chung H., Xu J., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Journal of Clinical Oncology 2009, 27:15s. [Abstract 4556].
47. Lordick F., Bang Y.J., Kang Y.K., et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. European Journal of Cancer 2007, 5:271. [Abstract 3541].
48. Ye Y.W., Fu H., Zhou Y., et al. Study on the different expression of molecular markers between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features. Digestive Surgery 2009, 26:384-391.
49. Berx G., Becker K.F., Hofler H., van Roy F. Mutations of the human E-cadherin (CDH1) gene. Human Mutation 1998, 12:226-237.
50. College of American Pathologists. HER2 testing guidelines and resources. Available from: ; 2010 [accessed 28.04.12]. http://www.cap.org/.
51. Gómez-Martin C., Concha A., Corominas J.M., et al. Consensus of the Spanish society of medical oncology (SEOM) and Spanish society of pathology (SEAP) for HER2 testing in gastric carcinoma. Clinical and Translational Oncology 2011, 13:636-651.
52. Ross J.S. Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?. Journal of Clinical Oncology 2010, 28:4293-4295.
53. Reichelt U., Duesedau P., Tsourlakis C., et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathology 2007, 20:120-129.
54. Marx A.H., Tharun L., Muth J., et al. HER-2 amplification is highly homogeneous in gastric cancer. Human Pathology 2009, 40:769-777.
55. Bozzetti C., Negri F.V., Lagrasta C.A., et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. British Journal of Cancer 2011, 104:1372-1376.
56. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 2009, 27:5838-5847.
57. Ajani J.A., Rodriguez W., Bodoky G., et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology 2010, 28:1547-1553.
58. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology 2000, 18:2648-2657.
59. Satoh T., Leon J., Lopez R.I., et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. Gastrointestinal cancers symposium 2010, [Abstract 7].
60. Shiroiwa T., Fukuda T., Shimouma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomized ToGA trial. British Journal of Cancer 2011, 105:1273-1278.
61. Hegewisch-Becker S., Moorahrend E., Kröning H., et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): findings from the German noninterventional study HerMES. Journal of Clinical Oncology 2012, 30s. [Abstract 4065].
62. Ghosh R., Narasanna A., Wang S.E., et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research 2011, 71:1871-1882.
63. Grávalos C., Gómez-Martín C., Rivera F., et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clinical and Translational Oncology 2011, 13:179-184.
64. von Minckwitz G., du Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. Journal of Clinical Oncology 2009, 12:1999-2006.
65. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 2010, 28:1124-1130.
66. Takiuchi H. Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials. Gastric Cancer 2011, 14:206-211.
67. Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer 2011, 47:2306-2314.
68. Kang J., Lee S., Lim D., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology 2012, 30:1513-1518.
69. Wong H., Leung R., Kwong A., et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer. Oncologist 2011, 16:1535-1546.
70. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 2012, 366:883-892.
71. Velho S., Oliveira C., Ferreira A., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. European Journal of Cancer 2005, 41:1649-1654.
72. Phillips W.A., Russell S.E., Ciavarella M.L., et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. International Journal of Cancer 2006, 118:2644-2646.
73. Nahta R., Yuan L.X., Zhang B., et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Research 2005, 65:11118-11128.
74. Nahta R., Takahashi T., Ueno N.T., et al. p27(kipl) down-regulation is associated with trastuzumab resistance in patients. Cancer Research 2004, 64:3981-3986.
75. Im S.A., Lee K.E., Nam E., et al. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005, 91:513-521.
76. Wen Y.G., Wang Q., Zhou C.Z., et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncology Reports 2010, 24:89-95.
77. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
78. Price-Schiavi S.A., Jepson S., Li P., et al. Rat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism of herceptin resistance. International Journal of Cancer 2002, 99:783-791.
79. Fessler S.P., Wotkowicz M.T., Mahanta S.K., Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Research and Treatment 2009, 118:113-124.
80. Citri A., Kochupurakkal B.S., Yarden Y. The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004, 3:51-60.
81. Lang S.A., Klein D., Moser C., et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Molecular Cancer Therapeutics 2007, 6:1123-1132.
82. Joensuu H., Sperinde J., Leinonen M., et al. Very high quantitative tumour HER2 content and outcome in early breast cancer. Annals of Oncology 2011, 22:2007-2013.
83. Bates M., Sperinde J., Köstler W.J., et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of Oncology 2011, 22:2014-2020.
84. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute 2007, 99:628-638.
85. Bender L.M., Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Frontiers in Bioscience 2008, 13:3906-3912.
86. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research 2008, 68:1471-1477.
87. Gajria D., Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy 2011, 11:263-275.
88. Gallardo A., Lerma E., Escuin D., et al. Increased signalling of EGFR and IGFIR, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. British Journal of Cancer 2012, 106:1367-1373.
89. Miller T.W., Forbes J.T., Shah C.H., et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of her2 inhibitors against her2-overexpressing cancer cells. Clinical Cancer Research 2009, 15:7266-7276.
90. Andre F., Campone M., OóRegan R., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. Journal of Clinical Oncology 2010, 28:5110-5115.
91. Morrow P.K., Wulf G.M., Ensor J., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. Journal of Clinical Oncology 2011, 29:3126-3132.
92. Van Cutsem E., Yeh K.-H., Bang Y.-J., et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. Journal of Clinical Oncology 2012, 30:4s. [Abstract LBA3].
93. Lang S.A., Christina H., Moser C., et al. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochimica et Biophysica Acta 2010, 1803:435-442.
94. Xue Q., Hopkins B., Perruzzi C., et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Research 2008, 68:9551-9557.
95. Lee K.H., Lee J.H., Han S.W., et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Science 2011, 102:1388-1395.
96. An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-positive advanced gastric cancer. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01402401.
97. Barok M., Tanner M., Köninki K., Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Letters 2011, 306:171-179.
98. Blackwell K.L., Miles D., Gianni L., et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. Journal of Clinical Oncology 2012, 30(Suppl.). [Abstract LBA1].
99. Yamashita-Kashima Y., Iijima S., Yorozu K., et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clinical Cancer Research 2011, 17:5060-5070.
100. Yamashita-Kashima Y., Shu S., Harada N., et al. Potentiation of trastuzumab emtansine (T-DM1)-driven antitumor activity by pertuzumab in a HER2-positive gastric cancer model. Journal of Clinical Oncology 2012, 30s. [Abstract e13502].
101. Baselga J., Gelmon K.A., Verma S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology 2010, 28:1138-1144.
102. Cortés J., Fumoleau P., Bianchi G.V., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 2012, 30:1594-1600.
103. Nam H.-J., Ching K.A., Kan J., et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Molecular Cancer Therapeutics 2012, 11:439-451.
104. Nam H.-J., Kim H.-P., Yoon Y.-K., et al. Antitumor activity of HM781-36B, an irreversible pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Letters 2011, 302:155-165.
105. Oh D.-Y., Lee K.-W., Cho J.Y., et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. Journal of Clinical Oncology 2012, 30:4s. [Abstract 54].
106. Janjigian Y.Y., Ilson D., Kelsen D.P., et al. A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer. Journal of Clinical Oncology 2012, 30s. [Abstract TPS4144].
107. Ritter C.A., Perez-Torres M., Rinehart C., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErB receptor network. Clinical Cancer Research 2007, 13:4909-4919.
108. Nahta R., Yuan L.X., Du Y., et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Molecular Cancer Therapeutics 2007, 6:667-674.
109. Kim J.W., Kim H.P., Im S.A., et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters 2008, 272:296-306.
110. Satoh T., Bang Y., Wang J., et al. Interim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. Journal of Clinical Oncology 2010, 28:15s. [Abstract 4057].
111. LaBonte M.J., Manegold P.C., Wilson P.M., et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. International Journal of Cancer 2009, 125:2957-2969.
112. Iqbal S., Goldman B., Fenoglio-Preiser C.M., et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of Oncology 2011, 22:2610-2615.
113. Hecht J., Bang Y., Sobrero A., et al. A phase III study of CapeOx +/- lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. European Journal of Cancer 2009, 7s. [Abstract 385].
114. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research 2008, 68:1471-1477.
115. Chen Ch-T, Kim H., Liska D., et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Molecular Cancer Therapeutics 2012, [Epub ahead of print]. 10.1158/1535-7163.MCT-11-0754.
116. Lennerz J.K., Kwak E.L., Ackerman A., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology 2011, 29:4803-4810.
117. Kubicka S., Claas C., Staab S., et al. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes. Helicobacter pylori infection, and prognosis. Digestive Diseases and Sciences 2002, 47:114-121.
118. Oliner K.S., Tang R., Anderson A., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab or placebo in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. Journal of Clinical Oncology 2012, 30s. [Abstract 4005].
119. Kataoka Y., Mukohara T., Tomioka H., et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase Networks. Investigational New Drugs 2011, [Epub ahead of print]. 10.1007/s10637-011-9699-0.
120. Phase I Trial of Intraperitoneal 212Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy. ClinicalTrials.gov. Available from: [accessed 25.05.12]. http://www.clinicaltrials.gov/ct2/show/NCT01384253.
121. Disis M.L., Wallace D.R., Gooley T.A., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology 2009, 27:4685-4692.